129 related articles for article (PubMed ID: 36630266)
1. Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients.
Nyangwara VA; Mazhindu T; Chikwambi Z; Masimirembwa C; Campbell TB; Borok M; Ndlovu N
Br J Clin Pharmacol; 2023 Jan; ():. PubMed ID: 36630266
[TBL] [Abstract][Full Text] [Related]
2. The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors.
Gündüz A; Duman D; Başbinar Y; Taşdelen B; Küpeli S; Karpuz D
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e65-e70. PubMed ID: 37828659
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.
Vargas-Neri JL; Carleton B; Ross CJ; Medeiros M; Castañeda-Hernández G; Clark P
Pharmacogenomics; 2022 Apr; 23(5):291-301. PubMed ID: 35147047
[No Abstract] [Full Text] [Related]
4. Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study.
Zolk O; von dem Knesebeck A; Graf N; Simon T; Hero B; Abdul-Khaliq H; Abd El Rahman M; Spix C; Mayer B; Elsner S; Gebauer J; Langer T
JMIR Res Protoc; 2022 Feb; 11(2):e27898. PubMed ID: 35175211
[TBL] [Abstract][Full Text] [Related]
5. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity.
Siemens A; Rassekh SR; Ross CJD; Carleton BC
Ther Drug Monit; 2023 Jun; 45(3):337-344. PubMed ID: 36728273
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
Aminkeng F; Ross CJ; Rassekh SR; Hwang S; Rieder MJ; Bhavsar AP; Smith A; Sanatani S; Gelmon KA; Bernstein D; Hayden MR; Amstutz U; Carleton BC;
Br J Clin Pharmacol; 2016 Sep; 82(3):683-95. PubMed ID: 27197003
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
Chang VY; Wang JJ
Curr Oncol Rep; 2018 Apr; 20(7):52. PubMed ID: 29713898
[TBL] [Abstract][Full Text] [Related]
8. Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.
Magdy T; Jouni M; Kuo HH; Weddle CJ; Lyra-Leite D; Fonoudi H; Romero-Tejeda M; Gharib M; Javed H; Fajardo G; Ross CJD; Carleton BC; Bernstein D; Burridge PW
Circulation; 2022 Jan; 145(4):279-294. PubMed ID: 34874743
[TBL] [Abstract][Full Text] [Related]
9. Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.
Christidi E; Huang H; Shafaattalab S; Maillet A; Lin E; Huang K; Laksman Z; Davis MK; Tibbits GF; Brunham LR
Sci Rep; 2020 Jun; 10(1):10363. PubMed ID: 32587261
[TBL] [Abstract][Full Text] [Related]
10. RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.
Magdy T; Jiang Z; Jouni M; Fonoudi H; Lyra-Leite D; Jung G; Romero-Tejeda M; Kuo HH; Fetterman KA; Gharib M; Burmeister BT; Zhao M; Sapkota Y; Ross CJ; Carleton BC; Bernstein D; Burridge PW
Cell Stem Cell; 2021 Dec; 28(12):2076-2089.e7. PubMed ID: 34525346
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.
Linschoten M; Teske AJ; Cramer MJ; van der Wall E; Asselbergs FW
Circ Genom Precis Med; 2018 Jan; 11(1):e001753. PubMed ID: 29557343
[TBL] [Abstract][Full Text] [Related]
12. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR;
Pediatr Blood Cancer; 2013 Aug; 60(8):1375-81. PubMed ID: 23441093
[TBL] [Abstract][Full Text] [Related]
13. RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes.
Huang H; Christidi E; Shafaattalab S; Davis MK; Tibbits GF; Brunham LR
Stem Cell Reports; 2022 Apr; 17(4):756-765. PubMed ID: 35364012
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
[TBL] [Abstract][Full Text] [Related]
15. Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes.
Fonoudi H; Jouni M; Cejas RB; Magdy T; Blancard M; Ge N; Shah DA; Lyra-Leite DM; Neupane A; Gharib M; Jiang Z; Sapkota Y; Burridge PW
JACC CardioOncol; 2024 Feb; 6(1):38-50. PubMed ID: 38510289
[TBL] [Abstract][Full Text] [Related]
16. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer.
Peddi PF; Fasching PA; Liu D; Quinaux E; Robert NJ; Valero V; Crown J; Falkson C; Brufsky A; Cunningham JM; Weinshilboum RM; Pienkowski T; Eiermann W; Martín M; Bee V; Wang X; Wang L; Yang E; Slamon DJ; Hurvitz SA
Clin Cancer Res; 2022 May; 28(9):1854-1862. PubMed ID: 35110416
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia.
Chikondowa P; Munkombwe D; Chikwambi Z; Kuona P; Masimirembwa C
Pharmacogenomics; 2023 Jun; 24(8):449-457. PubMed ID: 37248698
[TBL] [Abstract][Full Text] [Related]
18. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.
Hertz DL; Caram MV; Kidwell KM; Thibert JN; Gersch C; Seewald NJ; Smerage J; Rubenfire M; Henry NL; Cooney KA; Leja M; Griggs JJ; Rae JM
Pharmacogenomics; 2016 Feb; 17(3):231-40. PubMed ID: 26799497
[TBL] [Abstract][Full Text] [Related]
19. Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.
Vaidya TR; Mody H; Franco YL; Brown A; Ait-Oudhia S
AAPS J; 2021 Jan; 23(1):18. PubMed ID: 33404976
[TBL] [Abstract][Full Text] [Related]
20. Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study.
Mammadova J; Colin-Leitzinger C; Nguyen D; Mhaskar R; Ganesan S; Tang YH; Teng M; Ismail-Khan R; Gillis N
JCO Precis Oncol; 2023 Sep; 7():e2300208. PubMed ID: 37738545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
